Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions

Author(s): V.T. Labropoulou, A.D. Theocharis, A. Symeonidis, S.S. Skandalis, N.K. Karamanos and H.P. Kalofonos

Volume 18, Issue 11, 2011

Page: [1584 - 1598] Pages: 15

DOI: 10.2174/092986711795471275

Price: $65

Abstract

Bone disease is a common complication of metastatic solid tumors but also of primary hematological malignancies such as multiple myeloma. Our understanding of the molecular mechanisms underlying the development of bone disease by solid tumors and multiple myeloma has been significantly improved. A complex inter-dependence exists between bone disease and malignant cell growth, creating a vicious cycle of extensive bone destruction and tumor progression. Although myeloma and solid tumors share a number of common molecular pathogenetic mechanisms, they involve distinct pathophysiological pathways, resulting in osteoclastic bone resorption and inhibition of bone formation. In this review, we analyze the molecular mechanisms, involved in tumor-induced bone disease and discuss the current therapeutic approaches and the most recent clinical developments of emerging targeted therapies.

Keywords: Bone disease, cancer, multiple myeloma, molecular targeting, osteoblasts, osteoclasts


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy